Silence Therapeutics’ (SLN) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note issued to investors on Tuesday morning,Benzinga reports. Chardan Capital currently has a $55.00 price target on the stock.

Several other brokerages have also weighed in on SLN. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a research report on Tuesday, November 19th. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Monday. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Finally, Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Silence Therapeutics has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Trading Up 2.3 %

Shares of SLN opened at $6.60 on Tuesday. The stock’s 50 day moving average is $13.93 and its two-hundred day moving average is $17.25. Silence Therapeutics has a twelve month low of $5.81 and a twelve month high of $27.72. The firm has a market capitalization of $197.52 million, a PE ratio of -4.20 and a beta of 1.05.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Eventide Asset Management LLC purchased a new position in Silence Therapeutics in the third quarter valued at approximately $11,635,000. Parkman Healthcare Partners LLC raised its stake in shares of Silence Therapeutics by 71.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company’s stock valued at $9,051,000 after acquiring an additional 208,029 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Silence Therapeutics by 219.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company’s stock valued at $8,505,000 after acquiring an additional 321,300 shares during the period. Nicholas Investment Partners LP acquired a new position in shares of Silence Therapeutics during the 2nd quarter valued at $2,859,000. Finally, Janus Henderson Group PLC boosted its position in Silence Therapeutics by 32.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after purchasing an additional 268,250 shares during the period. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.